Intervention Protocol

Unboosted versus boosted atazanavir for reducing morbidity and mortality in people with HIV/AIDS

  1. Karen Cohen1,*,
  2. Tamara Kredo2,
  3. Renee de Waal1

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 11 JUL 2012

DOI: 10.1002/14651858.CD005418.pub2


How to Cite

Cohen K, Kredo T, de Waal R. Unboosted versus boosted atazanavir for reducing morbidity and mortality in people with HIV/AIDS (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD005418. DOI: 10.1002/14651858.CD005418.pub2.

Author Information

  1. 1

    University of Cape Town, Division of Clinical Pharmacology, Cape Town, South Africa

  2. 2

    South African Medical Research Council, South African Cochrane Centre, Tygerberg, Western Cape, South Africa

*Karen Cohen, Division of Clinical Pharmacology, University of Cape Town, Groote Schuur Hospital, Observatory, Cape Town, 7925, South Africa. karen.cohen@uct.ac.za.

Publication History

  1. Publication Status: Amended to reflect a change in scope (see 'What's new')
  2. Published Online: 11 JUL 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine whether unboosted atazanavir-containing regimens are more effective and safe than boosted atazanavir-containing regimens in reducing morbidity and mortality in people living with HIV/AIDS.